STOCKWATCH: Onyx at the crossroads of value destruction
This article was originally published in Scrip
Executive Summary
Apart from those under investigation by the US SEC for insider trading, Amgen’s exposed bid for Onyx Pharmaceuticals took most of us by surprise (scripintelligence.com, 01 July 2013). But now the intrigue for investors lies in watching the plot unfold, and seeing the choices that Onyx management and shareholders make.